Welsh rock star Mike Peters, the frontman of The Alarm band, has been declared in remission from aggressive cancer thanks to participating in an NHS drug trial. The 65-year-old was diagnosed with fast-growing lymphoma earlier this year, forcing him to cancel a US tour. Peters, who has been battling chronic lymphocytic leukaemia (CLL) for over 29 years, underwent experimental therapy at the Christie NHS Foundation Trust in Manchester, leading to the positive outcome.
Peters’ cancer took a sudden turn when doctors suspected Richter’s syndrome, a more aggressive lymphoma. This development led to the cancellation of his tour and immediate treatment at the Christie. The star’s swift action and the trial’s combination therapy of acalabrutinib with standard chemotherapy have proven successful, with recent scans showing Peters is now in remission.
Looking ahead, Peters may undergo a stem cell transplant to prevent a recurrence of leukaemia. He expressed gratitude for the trial, acknowledging that not all cases of Richter’s syndrome have positive outcomes. Peters praised the support of his fans, noting their encouragement during his health battle.
Peters’ wife, Jules, who has also overcome breast cancer, shared her perspective on facing cancer as a couple. The medical team at the Christie, including haematologist Professor Adrian Bloor, highlighted the rarity of Richter’s syndrome and the need for effective treatments.
The success of Peters’ treatment highlights the importance of ongoing research and clinical trials in combating cancer. Blood Cancer UK, which supports such research, expressed satisfaction at Peters’ progress and the impact of innovative treatment approaches.
While Peters remains focused on his recovery, he also aims to continue his music career. His determined spirit, along with the support of his loved ones and medical professionals, has been crucial throughout his health journey. The star’s journey serves as a testament to the power of medical advancements and the importance of early intervention in treating cancer.